Evaluation of Mucosal and Systemic Vaccine Responses by Cyclic di-GMP (CDG)-adjuvanted Protein Subunit Vaccines

Samira Mansouri; Lei Jin

doi:10.21769/BioProtoc.3217

Evaluation of Mucosal and Systemic Vaccine Responses by Cyclic di-GMP (CDG)-adjuvanted Protein Subunit Vaccines

Bio Protoc. 2019 Apr 20;9(8):e3217. doi: 10.21769/BioProtoc.3217.

Authors

Samira Mansouri¹, Lei Jin¹

Affiliation

¹ Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Florida, Gainesville, FL, USA.

Abstract

Intranasal administration of vaccine adjuvants directly deliver therapeutic agents to the lungs to induce potent lung mucosal immune responses. Cyclic di-GMP (CDG) is a promising mucosal vaccine adjuvant candidate capable of inducing protective immunity. This protocol describes an in vivo approach to induce and detect mucosal (lung) and systemic (blood and spleen) vaccine adjuvant responses of CDG. This protocol also includes the methods to detect both humoral and cellular immune responses of CDG adjuvant. Last, this protocol can be used to study other cyclic dinucleotides as mucosal vaccine adjuvants.

Keywords: Cyclic dinucleotides; Ex vivo recall assay; Humoral and cellular vaccine responses; Intranasal immunization; Mucosal vaccine adjuvant.